In preclinical models, the inhalation of a mixture of living Lactobacilli bacteria attenuated pulmonary inflammation and improved lung function and structure for the chronic lung diseases bronchopulmonary dysplasia and chronic obstructive pulmonary disease. This study determined the mechanism of this live biotherapeutic product — a powder mixture of living Lactobacilli bacteria — to reduce neutrophilic inflammation and reduce a broad swath of inflammatory markers in BPD and COPD.
Source:
www.sciencedaily.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
